aldosterone has been researched along with Endomyocardial Fibrosis in 32 studies
Endomyocardial Fibrosis: A condition characterized by the thickening of the ventricular ENDOCARDIUM and subendocardium (MYOCARDIUM), seen mostly in children and young adults in the TROPICAL CLIMATE. The fibrous tissue extends from the apex toward and often involves the HEART VALVES causing restrictive blood flow into the respective ventricles (CARDIOMYOPATHY, RESTRICTIVE).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to evaluate the effects of spironolactone on neurohumoral factors and left ventricular remodeling in patients with congestive heart failure (CHF)." | 9.09 | Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. ( Fujii, M; Hayashi, M; Kinoshita, M; Mabuchi, N; Maeda, K; Matsui, T; Matsumoto, T; Ohnishi, M; Sawaki, M; Tsutamoto, T; Tsutsui, T; Wada, A, 2001) |
| "Canrenone attenuates LV interstitial remodeling and reduces filling pressures in rats with postinfarction heart failure." | 7.71 | Effects of canrenone on myocardial reactive fibrosis in a rat model of postinfarction heart failure. ( Casaburi, C; Cittadini, A; Di Gianni, A; Monti, MG; Saccà, L; Saldamarco, L; Scherillo, G; Serpico, R; Vanasia, M, 2002) |
| "These results show that in old normotensive rats, spironolactone can markedly prevent cardiac and, to a lesser extent, arterial fibrosis and improve arterial stiffness, despite a lack of hypotensive effect." | 7.71 | Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. ( Benetos, A; Labat, C; Lacolley, P; Ledudal, K; Lucet, B; Safar, ME, 2001) |
| "Myocardial fibrosis, associated with increased expression of angiotensin converting enzyme (ACE) and bradykinin (BK) receptor binding at sites of tissue repair, accompanies chronic elevations in circulating angiotensin II (AngII) and/or aldosterone (ALDO) that simulate chronic cardiac failure." | 7.69 | Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. ( Ramires, FJ; Sun, Y; Weber, KT, 1997) |
| "In order to determine the relation between myocardial fibrosis and (1) angiotensin converting enzyme (ACE) binding density, (2) receptor binding of ACE-related peptides, angiotensin II (AngII) and bradykinin (BK), and (3) the regulation of myocardial ACE by circulating Ang II, we used in vitro quantitative autoradiography to localize and assess ACE ([125I]351A), AngII receptor (125I[Sar1, IIe8]AngII), and BK receptor ([125I]Tyr8) binding densities in the rat myocardium." | 7.69 | Fibrosis and myocardial ACE: possible substrate and independence from circulating angiotensin II. ( Sun, Y; Weber, KT, 1994) |
| "Aldosterone has a variety of detrimental effects on the heart and vasculature and is increasingly recognized as an important target in chronic heart failure, as illustrated by the Randomized Aldactone Evaluation Study." | 6.42 | The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. ( Davies, JI; Dawson, A; Struthers, AD, 2004) |
| "Aldosterone was shown to promote cardiac fibrosis in various experimental models." | 6.41 | Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. ( Alla, F; Dousset, B; Zannad, F, 2001) |
| "Aldosterone has been shown to have an acute arrhythmogenic effect as well as a potential detrimental effect on baroreflex function, a marker of prognosis in CHF." | 6.39 | Aldosterone escape during ACE inhibitor therapy in chronic heart failure. ( Struthers, AD, 1995) |
| "In untreated congestive heart failure, aldosterone plasma concentrations are elevated in proportion to the severity of the disease and are further increased by the use of diuretic treatment." | 6.39 | Aldosterone and heart failure. ( Zannad, F, 1995) |
| "Thus, in rats with aldosteronism, in which a reduction in effective refractory period was not evident, the mechanism for VA susceptibility is presumably linked to a decrease in conduction velocity and/or increased dispersion of refractoriness, probably caused by consequential myocardial fibrosis." | 5.37 | Spironolactone prevents the inducibility of ventricular tachyarrhythmia in rats with aldosteronism. ( Bellary, SR; de Jongh Curry, AL; Deshmukh, PA; Kamalov, G; Magotra, M; Schwender, FT; Sun, Y; Weber, KT, 2011) |
| "A total of 25 patients with primary aldosteronism caused by Conn's adenoma, 29 patients with renovascular hypertension, and 29 patients with essential hypertension (EHT) were included in the present study." | 5.33 | Role of aldosterone in left ventricular hypertrophy in hypertension. ( Fujii, K; Iida, M; Matsumura, K; Oka, M; Oniki, H, 2006) |
| "We sought to evaluate the effects of spironolactone on neurohumoral factors and left ventricular remodeling in patients with congestive heart failure (CHF)." | 5.09 | Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. ( Fujii, M; Hayashi, M; Kinoshita, M; Mabuchi, N; Maeda, K; Matsui, T; Matsumoto, T; Ohnishi, M; Sawaki, M; Tsutamoto, T; Tsutsui, T; Wada, A, 2001) |
| "Canrenone attenuates LV interstitial remodeling and reduces filling pressures in rats with postinfarction heart failure." | 3.71 | Effects of canrenone on myocardial reactive fibrosis in a rat model of postinfarction heart failure. ( Casaburi, C; Cittadini, A; Di Gianni, A; Monti, MG; Saccà, L; Saldamarco, L; Scherillo, G; Serpico, R; Vanasia, M, 2002) |
| "These results show that in old normotensive rats, spironolactone can markedly prevent cardiac and, to a lesser extent, arterial fibrosis and improve arterial stiffness, despite a lack of hypotensive effect." | 3.71 | Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. ( Benetos, A; Labat, C; Lacolley, P; Ledudal, K; Lucet, B; Safar, ME, 2001) |
| "Myocardial fibrosis, associated with increased expression of angiotensin converting enzyme (ACE) and bradykinin (BK) receptor binding at sites of tissue repair, accompanies chronic elevations in circulating angiotensin II (AngII) and/or aldosterone (ALDO) that simulate chronic cardiac failure." | 3.69 | Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. ( Ramires, FJ; Sun, Y; Weber, KT, 1997) |
| "In order to determine the relation between myocardial fibrosis and (1) angiotensin converting enzyme (ACE) binding density, (2) receptor binding of ACE-related peptides, angiotensin II (AngII) and bradykinin (BK), and (3) the regulation of myocardial ACE by circulating Ang II, we used in vitro quantitative autoradiography to localize and assess ACE ([125I]351A), AngII receptor (125I[Sar1, IIe8]AngII), and BK receptor ([125I]Tyr8) binding densities in the rat myocardium." | 3.69 | Fibrosis and myocardial ACE: possible substrate and independence from circulating angiotensin II. ( Sun, Y; Weber, KT, 1994) |
| "Hypertension is an important determinant of heart failure." | 2.42 | A neuroendocrine-immune interface. The immunostimulatory state of aldosteronism. ( Weber, KT, 2003) |
| "Aldosterone has a variety of detrimental effects on the heart and vasculature and is increasingly recognized as an important target in chronic heart failure, as illustrated by the Randomized Aldactone Evaluation Study." | 2.42 | The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade. ( Davies, JI; Dawson, A; Struthers, AD, 2004) |
| "Aldosterone was shown to promote cardiac fibrosis in various experimental models." | 2.41 | Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. ( Alla, F; Dousset, B; Zannad, F, 2001) |
| "Aldosterone has been shown to have an acute arrhythmogenic effect as well as a potential detrimental effect on baroreflex function, a marker of prognosis in CHF." | 2.39 | Aldosterone escape during ACE inhibitor therapy in chronic heart failure. ( Struthers, AD, 1995) |
| "Symptomatic heart failure is accompanied by diastolic ventricular dysfunction due largely to an extensive reactive and reparative fibrosis." | 2.39 | Structural remodelling of the heart by fibrous tissue: role of circulating hormones and locally produced peptides. ( Campbell, SE; Sun, Y; Weber, KT, 1995) |
| "In untreated congestive heart failure, aldosterone plasma concentrations are elevated in proportion to the severity of the disease and are further increased by the use of diuretic treatment." | 2.39 | Aldosterone and heart failure. ( Zannad, F, 1995) |
| " Experimental data are presented to indicate: a) endogenous or exogenous elevations in plasma angiotensin II are associated with acute cardiac myocyte necrosis and subsequent microscopic scarring; b) chronic elevations in plasma aldosterone (ALDO), relative to Na+ intake, are associated with a perivascular and interstitial fibrosis of the coronary and systemic circulations and are also seen in response to chronic administration of the mineralocorticoid hormone deoxycorticosterone (DOC); and c) chronic mineralocorticoid excess, due to ALDO or DOC, is associated with enhanced urinary K+ excretion, cardiac myocyte necrosis and scarring." | 2.38 | Myocardial fibrosis: role of angiotensin II and aldosterone. ( Brilla, CG; Campbell, SE; Guarda, E; Sriram, K; Weber, KT; Zhou, G, 1993) |
| "Thus, in rats with aldosteronism, in which a reduction in effective refractory period was not evident, the mechanism for VA susceptibility is presumably linked to a decrease in conduction velocity and/or increased dispersion of refractoriness, probably caused by consequential myocardial fibrosis." | 1.37 | Spironolactone prevents the inducibility of ventricular tachyarrhythmia in rats with aldosteronism. ( Bellary, SR; de Jongh Curry, AL; Deshmukh, PA; Kamalov, G; Magotra, M; Schwender, FT; Sun, Y; Weber, KT, 2011) |
| "A total of 25 patients with primary aldosteronism caused by Conn's adenoma, 29 patients with renovascular hypertension, and 29 patients with essential hypertension (EHT) were included in the present study." | 1.33 | Role of aldosterone in left ventricular hypertrophy in hypertension. ( Fujii, K; Iida, M; Matsumura, K; Oka, M; Oniki, H, 2006) |
| "Thus aldosterone and salt treatment in uninephrectomized rats led to severe hypertension and the development of a vascular inflammatory phenotype in the heart, which may represent one mechanism by which aldosterone contributes to myocardial disease." | 1.31 | Aldosterone induces a vascular inflammatory phenotype in the rat heart. ( Blomme, EA; Delyani, JA; Frierdich, GE; Kekec, BK; McMahon, EG; Nachowiak, DA; Rocha, R; Rudolph, AE, 2002) |
| " Thus, in the presence of enhanced sodium intake, chronic administration of ALDO or DOCA are associated with collagen accumulation in the myocardium, whereas with the mineralocorticoid-like compound GA, myocardial fibrosis was not seen." | 1.28 | Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. ( Brilla, CG; Weber, KT, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 16 (50.00) | 18.2507 |
| 2000's | 14 (43.75) | 29.6817 |
| 2010's | 2 (6.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lavall, D | 1 |
| Schuster, P | 1 |
| Jacobs, N | 1 |
| Kazakov, A | 1 |
| Böhm, M | 1 |
| Laufs, U | 1 |
| Mori, T | 1 |
| Kurumazuka, D | 1 |
| Matsumoto, C | 1 |
| Shirakawa, H | 1 |
| Kimura, S | 1 |
| Kitada, K | 1 |
| Kobayashi, K | 1 |
| Matsuda, H | 1 |
| Hayashi, T | 1 |
| Kitaura, Y | 1 |
| Matsumura, Y | 1 |
| Deshmukh, PA | 1 |
| Bellary, SR | 1 |
| Schwender, FT | 1 |
| Kamalov, G | 1 |
| Magotra, M | 1 |
| de Jongh Curry, AL | 1 |
| Sun, Y | 6 |
| Weber, KT | 12 |
| Sanderson, JE | 1 |
| Cittadini, A | 1 |
| Casaburi, C | 1 |
| Monti, MG | 1 |
| Di Gianni, A | 1 |
| Serpico, R | 1 |
| Scherillo, G | 1 |
| Saldamarco, L | 1 |
| Vanasia, M | 1 |
| Saccà, L | 1 |
| Rocha, R | 1 |
| Rudolph, AE | 1 |
| Frierdich, GE | 1 |
| Nachowiak, DA | 1 |
| Kekec, BK | 1 |
| Blomme, EA | 1 |
| McMahon, EG | 1 |
| Delyani, JA | 1 |
| Dawson, A | 1 |
| Davies, JI | 1 |
| Struthers, AD | 3 |
| Rossi, GP | 1 |
| Matsumura, K | 1 |
| Fujii, K | 1 |
| Oniki, H | 1 |
| Oka, M | 1 |
| Iida, M | 1 |
| Johar, S | 1 |
| Cave, AC | 1 |
| Narayanapanicker, A | 1 |
| Grieve, DJ | 1 |
| Shah, AM | 1 |
| Burnett, JC | 1 |
| Brilla, CG | 6 |
| Maisch, B | 2 |
| Rupp, H | 2 |
| Funck, R | 2 |
| Zhou, G | 2 |
| Campbell, SE | 4 |
| Slight, SH | 1 |
| Ganjam, VK | 1 |
| Griffing, GT | 1 |
| Swinfard, RW | 1 |
| Diaz-Arias, AA | 1 |
| Young, M | 2 |
| Fullerton, M | 1 |
| Dilley, R | 1 |
| Funder, J | 1 |
| Guarda, E | 1 |
| Sriram, K | 1 |
| Zannad, F | 2 |
| Ramires, FJ | 1 |
| Lacolley, P | 1 |
| Safar, ME | 1 |
| Lucet, B | 1 |
| Ledudal, K | 1 |
| Labat, C | 1 |
| Benetos, A | 1 |
| Tsutamoto, T | 1 |
| Wada, A | 1 |
| Maeda, K | 1 |
| Mabuchi, N | 1 |
| Hayashi, M | 1 |
| Tsutsui, T | 1 |
| Ohnishi, M | 1 |
| Sawaki, M | 1 |
| Fujii, M | 1 |
| Matsumoto, T | 1 |
| Matsui, T | 1 |
| Kinoshita, M | 1 |
| Dousset, B | 1 |
| Alla, F | 1 |
| Funder, JW | 1 |
| Janicki, JS | 1 |
| Reddy, HK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| E_Stethoscope : Portable Digital Auscultation Based on Wireless Sensor Node to Diagnose Diastolic Dysfunction in Hypertensive Heart Disease[NCT02809040] | 60 participants (Anticipated) | Observational | 2015-02-28 | Active, not recruiting | |||
| A Prospective Randomized Placebo-controlled Study of the Effect of Eplerenone on Left Ventricular Diastolic Function in Women Receiving Anthracycline Therapy for Breast Cancer[NCT01708798] | Phase 2/Phase 3 | 44 participants (Actual) | Interventional | 2014-05-31 | Terminated (stopped due to Futility) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for aldosterone and Endomyocardial Fibrosis
| Article | Year |
|---|---|
A neuroendocrine-immune interface. The immunostimulatory state of aldosteronism.
Topics: Aldosterone; Antioxidants; Cytokines; Endomyocardial Fibrosis; Heart Failure; Humans; Hyperaldostero | 2003 |
The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade.
Topics: Aldosterone; Autonomic Nervous System Diseases; Endomyocardial Fibrosis; Eplerenone; Heart Failure; | 2004 |
Natriuretic peptides and remodeling in heart failure.
Topics: Aldosterone; Animals; Cardiotonic Agents; Disease Progression; Dose-Response Relationship, Drug; End | 2005 |
Pharmacological modulation of cardiac fibroblast function.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomyopathy, Dilated; Collagen; E | 1995 |
Myocardial fibrosis: role of angiotensin II and aldosterone.
Topics: Aldosterone; Angiotensin II; Animals; Dipeptides; Endomyocardial Fibrosis; Heart; Humans; Lisinopril | 1993 |
Aldosterone escape during ACE inhibitor therapy in chronic heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Chronic Disease; Drug T | 1995 |
Structural remodelling of the heart by fibrous tissue: role of circulating hormones and locally produced peptides.
Topics: Aldosterone; Angiotensin II; Cardiac Volume; Catecholamines; Diastole; Endocardium; Endomyocardial F | 1995 |
Aldosterone and heart failure.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomegaly; Endomyocardial Fibrosi | 1995 |
The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure.
Topics: Adult; Aldosterone; Cardiomyopathy, Hypertrophic; Cell Division; Collagen; Connective Tissue; Corona | 1995 |
Cardiac remodelling by fibrous tissue: role of local factors and circulating hormones.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Endomyocardial Fibro | 1998 |
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2001 |
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2001 |
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2001 |
Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; An | 2001 |
Myocardial fibrosis and the renin-angiotensin-aldosterone system.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Line; Endomyoca | 1992 |
1 trial available for aldosterone and Endomyocardial Fibrosis
| Article | Year |
|---|---|
Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.
Topics: Aged; Aldosterone; Cardiac Volume; Endomyocardial Fibrosis; Female; Follow-Up Studies; Heart Failure | 2001 |
19 other studies available for aldosterone and Endomyocardial Fibrosis
| Article | Year |
|---|---|
Rac1 GTPase regulates 11β hydroxysteroid dehydrogenase type 2 and fibrotic remodeling.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Animals; Cell Line; Connective Tissue Grow | 2017 |
Dietary salt restriction activates mineralocorticoid receptor signaling in volume-overloaded heart failure.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Body Weight; Cell Size; Contraindications; Diet, So | 2009 |
Spironolactone prevents the inducibility of ventricular tachyarrhythmia in rats with aldosteronism.
Topics: Aldosterone; Animals; Blood Pressure; Body Weight; Collagen; Electric Stimulation; Electrocardiograp | 2011 |
New treatments for myocardial fibrosis.
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Canrenone; Clinical Trials as Topic; | 2002 |
Effects of canrenone on myocardial reactive fibrosis in a rat model of postinfarction heart failure.
Topics: Administration, Oral; Aldosterone; Animals; Canrenone; Collagen; Cyclodextrins; Disease Models, Anim | 2002 |
Aldosterone induces a vascular inflammatory phenotype in the rat heart.
Topics: Aldosterone; Animals; Blood Pressure; Chemokine CCL2; Coronary Vessels; Cyclooxygenase 2; Endomyocar | 2002 |
Cardiac consequences of aldosterone excess in human hypertension.
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin II; Blood Pressure; Calcium Channel Blockers; | 2006 |
Role of aldosterone in left ventricular hypertrophy in hypertension.
Topics: Adrenergic beta-Antagonists; Adrenocortical Adenoma; Adult; Aldosterone; Angiotensin II; Blood Press | 2006 |
Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase.
Topics: Aldosterone; Angiotensin II; Animals; DNA Primers; Endomyocardial Fibrosis; Matrix Metalloproteinase | 2006 |
Chronic mineralocorticoid excess and cardiovascular remodeling.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Adenoma; Adrenal Gland Neoplasms; Adrenal Glands; Adrenal Hyp | 1995 |
Adrenal steroids and cardiac fibrosis.
Topics: Aldosterone; Animals; Corticosterone; Desoxycorticosterone; Endomyocardial Fibrosis; Male; Mifeprist | 1995 |
Mineralocorticoids, hypertension, and cardiac fibrosis.
Topics: Aldosterone; Animals; Blood Pressure; Collagen; Desoxycorticosterone; Endomyocardial Fibrosis; Hydro | 1994 |
Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion.
Topics: Aldosterone; Angiotensin II; Animals; Aorta; Autoradiography; Binding Sites; Endomyocardial Fibrosis | 1997 |
Fibrosis and myocardial ACE: possible substrate and independence from circulating angiotensin II.
Topics: Aldosterone; Angiotensin II; Animals; Autoradiography; Endomyocardial Fibrosis; Female; Fibrosis; Ma | 1994 |
Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats.
Topics: Age Factors; Aldosterone; Animals; Aorta; Carotid Arteries; Endomyocardial Fibrosis; Fibrosis; Hemod | 2001 |
Evidence for myocardial synthesis of aldosterone producing myocardial fibrosis in man.
Topics: Aldosterone; Endomyocardial Fibrosis; Humans; Myocardium | 2002 |
Aldosterone, cardiac fibrosis, und der freischütz.
Topics: Aldosterone; Animals; Endomyocardial Fibrosis; Humans; Receptors, Mineralocorticoid | 1992 |
Mineralocorticoid excess, dietary sodium, and myocardial fibrosis.
Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Collagen; Desoxycorticosterone; Endomyocardial F | 1992 |
Myocardial fibrosis: role of ventricular systolic pressure, arterial hypertension, and circulating hormones.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Disease Models, Animal; Endomyocardial Fibrosi | 1991 |